In the early nineties, Jacques Galipeau was outside his native Canada, training at the Tufts New England Medical Center in Boston. It was an exciting time to be a young hematologist. The dream of gene therapy was becoming a reality, and with it came the promise of potential cures for the likes of sickle cell disease and thalassemia.
Fast forward, and we find a man who has ascended to lofty heights. At the recent 2022 meeting of the International Society for Cell & Gene Therapy, Galipeau was crowned as its new president. Here, we quiz Galipeau about the present and future of advanced medicine.
Well, the field has matured since the early nineties. Its worth remembering that the proof-of-concept for applying cell and gene therapies in humans arrived more than 30 years ago. Now, we have approved products! The first live cell vaccine approved by the FDA was Provenge in 2010. More recently, weve had the whole CAR T story, and in Europe weve seen the approval of mesenchymal cells for Crohns-related skin complications. All in all, its a very nice buffet.
As Im university based, my work is in discovery understanding how cells tick and how to make a better mousetrap out of them. We also work more boldly, testing first-in-human studies that may grow legs and march toward further development. At the University of Wisconsin-Madison, we have a special interest in virus-specific T cells and the version 2.0 of mesenchymal cells. As a scholar, these are my particular specialisms.
While wearing my ISCT hat, on the other hand, Im like a kid locked in a candy shop! There are so many exciting, emerging, and improved platforms, especially in immunotherapy and regenerative medicine. For some, the latter term is a dirty word because it has so often been bandied about as a catch-all everything for everybody. But now, were hearing about ongoing works like the clinical trials of induced pluripotent stem (IPS) cell-derived dopaminergic neurons for Parkinson's disease an excellent example of a highly promising regenerative medicine.
Regenerative medicines are replacement therapies, but the definition has now broadened to include all somatic cell therapies. Historically, regenerative medicine was all about stem cells, but more recently we have realized that there are many cells and tissues that can be used as living therapeutics, while having nothing to do with stem cells. For example, lymphoid cells and live tumor cell vaccines.
Absolutely. We humans are gregarious simians. Chimps dont talk its all nonverbal. Humans deal in a great deal of nonverbal communication too, and that cant be replicated online. So much of the spontaneity and exchange is leached away through the virtual interface. Not to mention the drop in dopamine levels!
Offline serendipity cant be replicated either. Everybody has a story that proves it. You turn and say hello to the person behind you in a queue for lunch at an event, and the next thing you know youre launching a collaboration. That doesnt happen on Zoom, where everyone is just one rectangle in a grid of video feeds.
It was a bold bet. Between our CEO Queenie Jang, our outgoing president Bruce Levine, and myself, we knew that we would have to make the call by October 2021. Reading the signs, we made plans for an in person event, and the result was a smashing success the biggest turnout weve ever had at an international meeting. I also think it helped prove that in-person events should remain the gold standard, with virtual hybridity as a bonus that remains well worth considering. Recording events is another pandemic practice wed like to keep alive. Having those recordings for future reference and wider access is really valuable. We want these international events to be absolutely optimal because they only come once per year and attending them isnt cheap especially for our friends flying in from afar!
We all know workforce development is an emerging topic, but I was surprised by just how strong the appetite for and imperative from stakeholders was. Had I not attended in person, I never would have got that impression.
From the perspective of platforms, I was surprised by the explosion of clinical-stage startups in cancer immunotherapy. Back in old school advanced therapy, the only way you could modify immune effector cells was using retroviral vectors. But now, we are seeing an explosion of emerging disruptive platforms that could be game changers as far as nimbleness is concerned.
Our societys focus on translational manufacturing, regulations, and first-in-human trials really sets us apart. In those areas, the technologists working in the field are really important. Theres a whole army of them. Thats why, at ISCT this year, we had a day for the technologists Saturday, to be precise.
It was standing room only! And it was great to see such a real uptick in attendance from people who are in neither business nor science. These are the people who really do the up-close work, and we learned that they have a real hunger for networking, change, and best practices. The ISCT is a knowledge-transfer organization, so we are more than happy to sate these appetites.
Last of all, Ill mention the real explosion of interest in exosomes as a therapeutic modality. Its lending a second life to the already popular interest in mesenchymal cells. Depending on how you tickle them in the petri dish, they spit out exosomes through which many of their functional attributes are transferred to tissues. This is a brand new development that is taking off in parallel with cancer immunotherapy, replacement therapy, and IPS.
I think the answer will be woven from different strands. In the case of established, approved, effective approaches that rinse, wash, and repeat 1000 times in a row, automation is your most obvious ally. But when youre still carrying out investigational development when youre building the plane as you fly it you may need some hands! Lab work can be a science in the same way cooking is a science. You need tactility, and more than a little artistry.
You really cannot underestimate the importance of having hands and being human! Take the analogy of baking a chocolate cake. I might give the exact same recipe to Bob and to Bert. Bob makes a beautiful cake, and Bert makes a burnt mess. Good hands and good instincts; some people have them, and some people just dont.
Compounding that, so many of our platforms are not set in stone. Disruptive technologies are loose in this field, and the task of incorporating and optimizing them is a hands-on affair. And thats where the workforce comes in. ISCT pays a great deal of attention here because we excel as a knowledge transfer and networking organization. Were not a university we cant confer diplomas but the way we pass on best practices and knowhow does make us serve as a sort of cooking school, if I may stretch my chocolate cake metaphor a little further.
We bring in domain experts that understand the obstacles and the friction points, and introduce them to newbies people who may well be very clever and have excellent degrees, but who still need to learn the ropes, and how to avoid beginners mistakes. Of course, you cant stop after initiation. This is an ever-evolving field of ever-evolving platforms. Penning a curriculum is not much use because it will likely be out of date by the time youve completed the first draft.
At ISCT events, we dont try to operate as a substitute for universities or technical colleges, as thats not our remit. Rather than disseminating knowledge through lecturing, we use a roundtable format. We set up a panel of experts, sit them down together, and let the audience listen to their back-and-forth in real time. Its an extremely valuable way to educate people on topics that wont appear in print for another year. In short, our attendees walk away as slightly more developed and informed professionals.
Right now, everybody is focusing on the highly impactful cell therapeutic platforms that have met marketing approval and are now commercially deployed. This is especially true in the case of cancer immunotherapy space, and even for Takedas mesenchymal product, Alofisel. The challenges here really hinge on the different regulatory environments that shape them.
In Europe, deployment and commercial success is dictated predominantly by universal payers and national entities. The US will be more of a wild west as far as pricing and reimbursement are concerned. I have no magic solutions for my commercial friends, but I do aim to help them understand the best practices that can ensure both ROI, as well as the sustainability and deployability necessary for distributive justice. Balancing ROI and access is not just a moral question; if one overtakes the other, the platform may collapse. Over time, competition ought to bring the current prices down. As more products are rolled out and sorted according to their effectiveness, potency, and ability to improve human outcomes, it is my hope and expectation that they will position themselves in a sustainable manner.
That said, I am currently very interested in another aspect that complements pharmas traditional central manufacturing, hub-and-spoke model: the democratization of advanced cell therapy, manufacture, and deployment. Bone marrow transplants serve as a good example. These are cell therapies, but since regulation does not define them as an advanced cell therapy, they do not require oversight by the EMA or FDA. Everything from cell collection and manipulation to re-administration is carried out in academic health centers. Industry had no direct involvement in the development of bone marrow transplants.
Now, with the explosion of cell therapies, the relevant technologies are becoming increasingly simple, and the prices are ever more robust. It is becoming easier to imagine that hospitals and other places of care could serve as a complement to large-scale manufacturing, especially for autologous cell therapies or one patient/one donor paradigms. There's a lot of new money in this space geared toward not only the traditional model, but also these complementary models of deployment. Thats something I think we need to face, as the future comes knocking.
Originally posted here:
ISCT's New Leader on the Future of Cell and Gene Therapy - The Medicine Maker
- Embryonic Stem Cell Fact Sheet - University of WisconsinMadison - October 21st, 2022
- The longevity diet: Lots of beans and periodic fasts slow ageing - The New Daily - September 16th, 2022
- See-through zebrafish, new imaging method put blood stem cells in high-resolution spotlight - University of Wisconsin-Madison - August 14th, 2022
- Erik Ranheim to become chair of Department of Pathology and Laboratory Medicine - University of Wisconsin School of Medicine and Public Health - August 5th, 2022
- It's a Holland Hat Trick: College of Health Professor Gets Three Grant Notifications in One Day - University of Utah Health Sciences - August 5th, 2022
- How long-term Covid-19 immunity paves the way for universal Covid-19 vaccines - Vox.com - August 5th, 2022
- Delayed cord blood clamping: a health boost for babies, and potentially for others - La Crosse Tribune - July 19th, 2022
- Neural stem cells: developmental mechanisms and disease modeling - June 13th, 2022
- The benefits and risks of stem cell technology - PMC - June 13th, 2022
- Hunters, Hearing Loss, and New Tech to Fix it - MeatEater - June 13th, 2022
- Cryopreservation of Hematopoietic Stem Cells - January 20th, 2022
- Post from Community: STEM Forward to honor STEM outreach and engineering excellence at the 69th annual celebration of STEM virtual event - Milwaukee... - January 20th, 2022
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - January 5th, 2022
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- FDA Approval of Jakafi for Chronic GVHD Provides Another Option, But 'More Work Needs to Be Done' - Curetoday.com - October 5th, 2021
- Researchers May Have Found The Gene Responsible For Cellular Aging - Anti Aging News - December 4th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - December 4th, 2020
- Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - Khabar South Asia - December 4th, 2020
- Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - Royal Sutton News - October 29th, 2020
- Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty - June 4th, 2020
- Clinical prospects for stem cells begin to emerge - April 28th, 2020
- Answering your sweet onion question and the science of why onions make you cry - Green Bay Press Gazette - April 28th, 2020
- New technique developed to treat hardening of internal organs - WNDU-TV - March 4th, 2020
- Scientists Grapple with US Restrictions on Fetal Tissue Research - The Scientist - March 4th, 2020
- Cells carrying Parkinson's mutation could lead to new model for studying disease - University of Wisconsin-Madison - March 4th, 2020
- Deer hunter or Bambi lover: What you should know about chronic wasting disease - Ohio's Country Journal and Ohio Ag Net - February 14th, 2020
- Cord Tissue Cell Therapy | Wisconsin Stem Cell Therapy - January 29th, 2020
- The selling of CTE: How the 'Concussion' doctor has built a career on distorted science - Stars and Stripes - January 24th, 2020
- nation briefs - Daily Herald - January 5th, 2020
- Addressing Disparities in Cancer: Factors Influencing Care, Access and Outcomes - OncoZine - December 11th, 2019
- Ausman family thankful for recoveries, support from family and community - Chippewa Herald - November 28th, 2019
- Lab: Nightmares may help the brain prepare for frightening situations in real life - Metro Newspaper UK - November 28th, 2019
- Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton... - November 28th, 2019
- Development of the dopaminergic system - from stem cells ... - April 15th, 2019
- Stem Cell Therapy for Back Conditions Oconomowoc, WI - January 26th, 2019
- Wisconsin Stem Cell Clinic - Forward Healthy Lifestyles - December 31st, 2018
- Knee Conditions Milwaukee, WI | Wisconsin Stem Cell Therapy - November 1st, 2018
- Stem Cells for Hip Brookfield, WI | Wisconsin Stem Cell ... - October 26th, 2018
- Geron Official Affirms iPS Cells Are the Future of Stem ... - October 13th, 2018
- Laws Governing Stem Cell Research Wisconsin Right to Life - June 23rd, 2018
- Knee Conditions | Milwaukee, WI | Wisconsin Stem Cell - October 16th, 2017
- Sponsors World Stem Cell Summit - October 15th, 2017
- Stem Cell Therapy - Cendant Cellular Therapies - Denver ... - October 15th, 2017
- Madison man is first Hmong-American to get an MD-Ph.D. - Post-Bulletin - July 10th, 2017
- Stem cells | | News | UW-Madison - November 20th, 2016
- Public Outreach | Stem Cell and Regenerative Medicine Center - November 20th, 2016
- Chapter 34: Stem Cells - The Hastings Center - September 28th, 2016
- Wisconsin Stem Cell Therapy | Stem Cell Treatments - October 10th, 2015
- 1. Embryonic Stem Cells [Stem Cell Information] - October 1st, 2015
- WISCONSIN STEM CELL SYMPOSIUM - BTC Institute - October 1st, 2015
- How Stem Cells Work - HowStuffWorks - October 1st, 2015
- Variations in cell programs control cancer and normal stem ... - September 8th, 2015
- Local students take part in stem cell camp | Local | apg ... - August 1st, 2015
- Wisconsin Roundup: VC Funding, StartUp Health, Stem Cells ... - July 2nd, 2015
- Stem cell expert: Bart Starr treatment shows need for ... - June 29th, 2015
- Study Reveals How Imaging Technology Can Track Stem Cell ... - June 11th, 2015
- Wisconsin Stem Cell Now Issues and Legislation - June 11th, 2015
- UW-Madison Heart Stem Cell Study Among American Heart ... - May 28th, 2015
- Whitehead Institute - News - 2008 - Human blood stem cells ... - May 1st, 2015
- Science meets art: 2015 Cool Science Images unveiled - April 11th, 2015
- Kentucky Fan Gets Life-Saving Stem Cell Donation From Univ. of Wisconsin Student - April 3rd, 2015
- Blood ties: Ky. basketball fan gets Wisconsin assist - April 2nd, 2015
- Wisconsin Stem Cell Roundtable (WiSCR) - Welcome to Stem ... - March 13th, 2015
- New insights into 3-D genome organization and genetic variability - March 10th, 2015
- UW Stem Cell Researchers Building a 'Retinal Patch' to ... - February 27th, 2015
- New Insights into 3D Genome Organization and Genetic Variability - February 18th, 2015
- First contracting human muscle grown in laboratory - January 14th, 2015
- Eye Researchers Awarded Grant for Stem-Cell Research in ... - January 3rd, 2015
- UW-Madison Stem Cell & Regenerative Medicine Center - December 27th, 2014
- Baby cells learn to communicate using the lsd1 gene - December 16th, 2014
- Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients - December 9th, 2014
- Research to Prevent Blindness, Inc. and the International Retinal Research Foundation Announce Catalyst Awards for AMD ... - December 4th, 2014
- James A. Thomson - Wisconsin Stem Cell Research Program - December 1st, 2014
- Programs - Cell and Regenerative Biology, University of ... - November 18th, 2014
- Morgridge Scientists Find Way to 'Keep the Lights on' for Cell Self-Renewal - November 13th, 2014
- BioEden the specialist tooth stem cell bank announce ... - November 12th, 2014
- Survival rates in pediatric umbilical cord transplants may indicate a new standard of care - October 30th, 2014
- UW-Madison senior Maria Estevez discusses women pursuing STEM fields - October 27th, 2014
- Cashton man goes from winning state award to battling cancer - October 12th, 2014
- Career Opportunities | Stem Cell and Regenerative Medicine ... - September 26th, 2014